Description

This program seeks to catalyze transformative advances in the development of rapid, minimally invasive, and affordable diagnostics for antimicrobial resistance (AMR) in lower respiratory tract infections (LRTIs), targeting global deployment. Supported by the Novo Nordisk Foundation, the grant funds early-stage, proof-of-concept research by interdisciplinary consortia, including microbiologists, clinicians, physicists, computer scientists, and other relevant experts. Projects should focus on innovative sample collection and processing, biomarker discovery, and predictive antimicrobial susceptibility testing, with a strong emphasis on solutions that enable direct-from-specimen, rapid, point-of-care diagnosis. The research must be anchored at a research institution or non-profit organization, and must provide substantial improvements over current diagnostic technologies, particularly for global and low-resource settings.